
Sentynl buys treatment for rare ageing disease
Biopharmaceutical company Sentynl Therapeutics has acquired Eiger Biopharmaceuticals’ approved treatment for the rare disease progeria. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL), in young people 12 months of age and older, are ultra-rare, fatal, genetic premature ageing diseases that accelerate mortality in young patients. Eiger’s… Read More













